Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls
Analysts issued multiple rating changes. Humana (HUM) was upgraded by Leerink to Outperform with a $513 target and by Piper Sandler to Overweight with a $463 target. Bloom Energy (BE), Sprouts (SFM), uniQure (QURE), and Core Scientific (CORZ) also saw upgrades. Las Vegas Sands (LVS) was downgraded to Hold by Argus. Other actions included P&G (PG), SiteOne (SITE), Capricor (CAPR), and Fannie Mae (FNMA).
How this was made
The 30-second read
Why it matters
The most tradable elements are the rating/PT changes with explicit theses: HUM upgrades versus a separate HUM downgrade, LVS downgrade tied to China/VIP pressure, and CAPR’s expected FDA complete response letter into an August 22 action date.
Market read
Traders can use the analyst PT/rating changes as near-term sentiment catalysts, with CAPR and LVS offering the clearest thesis-driven downside risk framing.
What to watch
For HUM, the article flags Stars cut-point uncertainty as a key unknown; for CAPR, the HOPE-3 FDA stance implies binary outcomes that can overwhelm valuation arguments.
Background
The piece is a multi-name analyst note roundup, with several firms changing ratings and price targets based on earnings power, regulatory expectations, and post-quarter performance.
Ticker impact
Leerink and Piper Sandler upgraded Humana to Outperform/Overweight with higher price targets, citing attractive 2028 earnings power and valuation.
Likely positive bias for HUM into the next few sessions, with volatility possible given Raymond James’ separate downgrade tied to Stars cut-point uncertainty.
Two upgrades with explicit PT increases are fresh catalysts, while a concurrent downgrade highlights unresolved regulatory/Stars-related variables.
Argus downgraded Las Vegas Sands to Hold from Buy, citing weak Chinese economy, VIP pressure, and compressed earnings multiple visibility.
Near-term downside or underperformance risk versus peers as the market digests the multiple-compression narrative.
The article provides a clear, thesis-driven downgrade with specific macro and regional visibility concerns.
Mizuho upgraded Bloom Energy to Outperform with a lower PT, pointing to a strong quarter with revenue and shipments beating expectations.
Mixed reaction possible: upgrades may lift sentiment, while the lower PT can cap upside.
The text includes both an upgrade and a PT reduction, implying the market may need to reconcile optimism with valuation discipline.
JPMorgan upgraded Sprouts Farmers Market to Overweight with a higher PT after the Q2 report, citing a positive sales growth inflection.
Moderately positive near-term bias, particularly if the market aligns with the inflection-point framing.
The upgrade is tied to a specific post-Q2 growth inflection claim and a concrete PT increase.
Wolfe Research upgraded uniQure to Outperform with a $65 PT, arguing the approval odds and AMT-130 case are stronger than the market appreciates.
Potential upside bias on the upgrade, though volatility remains high given the approval-probability debate referenced in the article.
The article provides a clear change in rating and PT plus a quantified probability model (70% vs <50% priced in).
Keefe Bruyette upgraded Core Scientific to Outperform with a higher PT, citing a near-term lease win totaling 529 MW of AMD-related leases.
Likely positive reaction potential as the lease award provides tangible near-term operating support.
The text includes a specific, measurable lease volume (529 MW) tied to the upgrade.
HSBC downgraded Procter & Gamble to Hold from Buy and cut its PT to $149, citing weak fiscal Q4 results and guidance implying another transition year.
Downside or relative underperformance risk for PG versus prior buy-rated positioning.
The article cites weak results and explicit guidance implications, which are direct drivers for valuation and sentiment.
Stifel downgraded SiteOne Landscape to Hold from Buy, cutting its PT to $100 and saying near-term share-performance questions are hard to counter.
Slight-to-moderate negative bias, with limited upside until the company addresses the performance concerns.
The article provides a clear rating/PT change and a rationale focused on near-term difficulty countering bull arguments.
Market effects
Broad read-through across managed care, consumer staples, gaming, biotech, and power/energy infrastructure via analyst rating changes.
LVS downgrade explicitly ties risk to China and Singapore recovery visibility, reinforcing regional demand sensitivity.
Biotech regulatory-risk framing (CAPR, QURE) can influence broader risk appetite in clinical-stage names.
Counterpoint
PT cuts alongside upgrades (BE) and multiple downgrades (HUM, PG, SITE, LVS) suggest the Street may be shifting from optimism to valuation discipline rather than signaling durable fundamental improvement.
Key entities
- companyHumana
Upgraded by two firms on attractive 2028 earnings power, but also downgraded by Raymond James citing Stars cut-point uncertainty.
- companyLas Vegas Sands
Downgraded by Argus to Hold due to weak China demand signals and compressed earnings multiple visibility.
- companyCapricor Therapeutics
Downgraded by Piper Sandler to Neutral, expecting another FDA complete response letter after HOPE-3 negative stance.
